Skip to main content
Premium Trial:

Request an Annual Quote

Taconic to Sell Medicyte's Hepatocyte Cell Strains

NEW YORK (GenomeWeb News) – Taconic and Medicyte announced a sales and marketing agreement covering Medicyte's products.

Under the terms of the deal, Taconic will promote and sell Medicyte's human primary Upcyte hepatocyte cell strains and corresponding media, which have been developed for in vitro applications. According to the companies, the deal strengthens Taconic's tADMET portfolio of models, and expands Medicyte's distribution and market visibility, while at the same time providing entry into new markets for its hepatocyte cell strains.

The tADMET products are genetically and tissue humanized mouse cells and in vitro tools and services for improving the predictability of drug response in humans. Translational research applications for tADMET include studies in drug metabolism, toxicology and safety, and infectious diseases of the liver.

Financial and other terms of the deal were not disclosed.

"Human hepatocytes are indispensable for many applications in research, drug screening, and development," Joris Braspenning, managing director of Medicyte, said in a statement. "However, the availability of primary human hepatocytes is limited and their quality is variable. With the Upcyte hepatocytes, we can bring predictive, reliable, and standardized cells on the market to close the gap."

Medicyte, based in Heidelberg, Germany, develops controlled, scalable, and standardized human primary cell products. Taconic, located in New York's Hudson River Valley, provides genetically engineered mouse and rat models and services.